Totally, these findings provide evidence indicating that combination therapy of GLP1 RAs with other antidiabetic medicine not only offers the advantages of complementary pharmacologies with better glycaemic control but also leads to a greater improvement in hepatic steatosis than the single use of GLP‐1 RAs. The gene discussed is GCG; the disease is fatty liver disease.